The C3 inhibitor pegcetacoplan and C5 inhibitor avacincaptad pegol has been FDA-approved as they are shown to significantly halt the atrophy progression in patients with geographic atrophy secondary to AMD. The gene discussed is C5; the disease is atrophic macular degeneration.